Biopharmaceuticals - Vaccine Manufacturing & Distribution
Strategic Profile
Zhifei operates an extensive service network supplying vaccines to over 30,000 vaccination points across 31 provinces in China. The company has built a proprietary cold chain system with real-time temperature monitoring, enabling safe long-distance vaccine transportation. This infrastructure provides competitive advantages in vaccine distribution across China's diverse healthcare landscape.
Cyborg Score Rationale
The company reported 2024 revenue of $3.6B (down 50.7% from 2023) and a market cap of $6.1B. Recent revenue decline and margin compression (-49.3% profit margin change) present headwinds, but strong R&D focus and market position in China's growing vaccine sector provide foundation for recovery.
Top Insights
2024 revenue declined 50.7% to $3.6B with net income down 75%, reflecting significant recent headwinds.
Zhifei operates five wholly-owned subsidiaries and a joint-stock subsidiary, with Beijing and Anhui entities designated as high-tech enterprises.
Product portfolio includes recombinant coronavirus vaccine, TB fusion protein, and meningococcal/hemophilus vaccines.
The company employs 7,220 people and holds the distinction of being China's first privately-run vaccine enterprise listed on ChiNext.
Named Competitors
Sinopharm — State-owned vaccine producer with extensive domestic network
Sinovac — Major Chinese vaccine manufacturer with global distribution
CanSino Biologics — Recombinant vaccine developer with COVID-19 portfolio
Recent Developments
(February 2026) ISS Governance QualityScore rated 7, with strong Audit pillar score of 9
(2024) Significant revenue contraction and profitability challenges reflect market dynamics
(Ongoing) Development of vaccines for emerging infectious diseases and continued international expansion efforts
Open the full interactive Chongqing Zhifei Biological Products Co., Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.